Supplementary Tables 1-4, Figure 1 from The Use of Transcriptional Profiling to Improve Personalized Diagnosis and Management of Cutaneous T-cell Lymphoma (CTCL)

Abstract

Supplementary Tables 1-4, Figure 1. Supplementary Table 1. Primers used for RT-PCR experiments. Supplementary Table 2. Detailed description of the 52 genes that fit into the three signature pattern expression model and their putative functions in CTCL and other malignancies. Supplementary Table 3. Multivariate analysis of patient characteristics that are associated with clinical disease progression. Supplementary Table 4. Description of genes that are able to distinguish CTCL from benign dermatoses and their putative roles in CTCL and other malignancies. Supplementary Figure 1. A. WIF1 (Wnt Inhibitory Factor 1) gene is expressed in normal skin and CTCL lesional skin in a subset of patients. B. Correlation of WIF1 expression in CTCL patients with disease progression. Kaplan-Meier analysis documents that loss of WIF1 expression is associated with poor CTCL disease progression (left panel, p=0.002). Disease progression is defined as a progression to a higher clinical stage and/or death. Loss of WIF1 is also associated with poor cancer specific survival (right panel, p=0.012).